{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T05:47:55Z","timestamp":1785044875000,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>The optimal antithrombotic regimen for patients without an indication for oral anticoagulation (OAC) after transcatheter aortic valve replacement (TAVR) remains unclear. We conducted a network meta-analysis of randomized controlled trials to clarify the best postoperative antithrombotic regimen. We searched literature databases including PubMed\/Medline and Cochrane up to June 2024. Safety endpoints included all-cause death, cardiovascular death, major\/life-threatening bleeding, and minor bleeding during follow-up. Efficacy endpoints encompassed ischaemic stroke transient ischemic attack (TIA), systemic embolism, hypoattenuated leaflet thickening (HALT), and reduced leaflet motion (RELM). Outcomes were assessed during the follow-up period specified in each trial (range:3\u201324 months). The results were statistically analyzed using R 4.3.2 and Stata 16 software. The final analysis included seven randomized controlled trials. Single antiplatelet therapy (SAPT) showed a lower incidence of major\/life-threatening bleeding compared to the direct oral anticoagulants (DOACs) group (OR: 0.68, 95% CI: 0.47\u20130.99, <jats:italic>P<\/jats:italic>\u2009=\u20090.002) during the 3\u201324 month post-TAVR period. However, no significant differences were found in other safety or efficacy endpoints. SAPT is the preferred treatment strategy for TAVR patients without anticoagulation indications.<\/jats:p><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p>identifier, PROSPERO registration number: CRD42024584735.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1496334","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T05:36:37Z","timestamp":1746768997000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Antithrombotic strategies after transcatheter aortic valve replacement a network meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Mengxiao","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1700456","article-title":"Surgical or transcatheter aortic-valve replacement in intermediate-risk patients","volume":"376","author":"Reardon","year":"2017","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e02","DOI":"10.15420\/icr.2019.24","article-title":"Anticoagulation after transcatheter aortic valve implantation: current Status","volume":"15","author":"Greco","year":"2020","journal-title":"Interv Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e6431","DOI":"10.7759\/cureus.6431","article-title":"Transcatheter aortic valve replacement versus surgical aortic valve replacement: a review of aortic stenosis management","volume":"11","author":"Sattar","year":"2019","journal-title":"Cureus"},{"key":"B4","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/17434440.2019.1674138","article-title":"Transcatheter aortic valve replacement: clinical safety and performance data","volume":"16","author":"van Baal","year":"2019","journal-title":"Expert Rev Med Devices"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1161\/CIR.0000000000000932","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"6781","DOI":"10.3390\/jcm11226781","article-title":"The efficacy and safety of direct oral anticoagulants versus standard of care in patients without an indication of anti-coagulants after transcatheter aortic valve replacement: a meta-analysis of randomized controlled trials","volume":"11","author":"Abuelazm","year":"2022","journal-title":"J Clin Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1055\/a-1496-8114","article-title":"Safety and efficacy of different antithrombotic strategies after transcatheter aortic valve implantation: a network meta-analysis","volume":"122","author":"Navarese","year":"2022","journal-title":"Thromb Haemost"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.jcin.2022.07.014","article-title":"Apixaban and valve thrombosis after transcatheter aortic valve replacement: the ATLANTIS-4D-CT randomized clinical trial substudy","volume":"15","author":"Montalescot","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"B10","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 Explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions\u20142019","author":"Higgins","year":"2019"},{"key":"B12","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1161\/CIRCULATIONAHA.122.059512","article-title":"Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR: the ADAPT-TAVR randomized clinical trial","volume":"146","author":"Park","year":"2022","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.amjcard.2011.07.049","article-title":"Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation","volume":"108","author":"Ussia","year":"2011","journal-title":"Am J Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.jcin.2017.04.014","article-title":"Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (aspirin versus aspirin\u2009+\u2009clopidogrel following transcatheter aortic valve implantation) randomized clinical trial","volume":"10","author":"Rodes-Cabau","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e009983","DOI":"10.1161\/CIRCINTERVENTIONS.120.009983","article-title":"Randomized trial of aspirin versus warfarin after transcatheter aortic valve replacement in low-risk patients","volume":"14","author":"Rogers","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"B16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1911426","article-title":"Reduced leaflet motion after transcatheter aortic-valve replacement","volume":"382","author":"De Backer","year":"2020","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1056\/NEJMoa2017815","article-title":"Aspirin with or without clopidogrel after transcatheter aortic-valve implantation","volume":"383","author":"Brouwer","year":"2020","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41569-019-0197-y","article-title":"TAVR Versus surgery in low-risk patients","volume":"16","author":"Huynh","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa1816885","article-title":"Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients","volume":"380","author":"Popma","year":"2019","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jcin.2018.10.047","article-title":"Tailoring antiplatelet therapy in patients undergoing transcatheter aortic valve replacement: navigating the unknown","volume":"12","author":"Capodanno","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1093\/eurheartj\/ehac290","article-title":"Antithrombotic therapy in patients undergoing transcatheter aortic valve replacement","volume":"43","author":"Han","year":"2022","journal-title":"Eur Heart J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.clinthera.2023.09.028","article-title":"Antithrombotic treatment after transcatheter valve interventions: current Status and future directions","volume":"46","author":"Maznyczka","year":"2024","journal-title":"Clin Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4103\/heartviews.heartviews_36_22","article-title":"Antithrombotic therapy after transcatheter aortic valve replacement","volume":"23","author":"Mousa","year":"2022","journal-title":"Heart Views"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.jcin.2021.06.020","article-title":"Antithrombotic therapy after transcatheter aortic valve replacement","volume":"14","author":"Capodanno","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2016.11.005","article-title":"Incidence, predictors, and mid-term outcomes of possible leaflet thrombosis after TAVR","author":"Yanagisawa","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.jcin.2022.08.003","article-title":"Anticoagulation and subclinical valve thrombosis after TAVR","volume":"15","author":"Dangas","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/S0140-6736(17)30757-2","article-title":"Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study","volume":"389","author":"Chakravarty","year":"2017","journal-title":"Lancet"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1496334\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T05:36:39Z","timestamp":1746768999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1496334\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":27,"alternative-id":["10.3389\/fcvm.2025.1496334"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1496334","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"article-number":"1496334"}}